MARKET

EXAS

EXAS

EXACT Sci
NASDAQ

Real-time Quotes | Nasdaq Last Sale

91.66
+5.36
+6.21%
Closed 18:53 07/08 EDT
OPEN
87.33
PREV CLOSE
86.30
HIGH
92.35
LOW
87.31
VOLUME
1.43M
TURNOVER
--
52 WEEK HIGH
123.99
52 WEEK LOW
35.25
MARKET CAP
13.74B
P/E (TTM)
-119.6137
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 15 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EXAS stock price target is 101.79 with a high estimate of 115.00 and a low estimate of 90.00.

EPS

EXAS News

More
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued
Simply Wall St. · 20h ago
Exact Sciences schedules annual meeting, second quarter 2020 earnings call
PR Newswire · 21h ago
Missed the telehealth stock boom? There's still time to get in with these stocks, Jefferies says
Jefferies told clients that names like Teladoc and Cigna, have the most to offer in the near and long term.
CNBC.com · 06/30 10:46
Citigroup Maintains Buy on Exact Sciences, Raises Price Target to $110
Citigroup maintains Exact Sciences (NASDAQ:EXAS) with a Buy and raises the price target from $100 to $110.
Benzinga · 06/25 11:24
Guardant Health's Blood Cancer Test Detects Early-Stage Colon Cancer
MotleyFool.com · 06/22 04:00
Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients
PR Newswire · 06/16 13:00
Exact Sciences Highlights Publication Of Results Showing Performance Of Oncotype DX Genomic Prostate Score
MADISON, Wis., June 16, 2020 /PRNewswire/ --Exact Sciences Corp. (NASDAQ:EXAS) today announced the publication of results highlighting the performance of the Oncotype DXGenomic Prostate Score®(GPS™)
Benzinga · 06/16 12:04
Why Is Exact Sciences (EXAS) Up 2.4% Since Last Earnings Report?
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 06/05 15:31

Industry

Biotechnology & Medical Research
+1.13%
Pharmaceuticals & Medical Research
+0.50%

Hot Stocks

Symbol
Price
%Change

About EXAS

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
More

Webull offers kinds of EXACT Sciences Corporation stock information, including NASDAQ:EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXAS stock methods without spending real money on the virtual paper trading platform.